Loading company…
Hangzhou biotech founded in 2017 developing immune-privileged cell and organ therapies, including gene-edited stem cell products.
Established in 2017 and based in Hangzhou, China, Qihan Biotech develops immune-privileged cell and organ platforms that can evade immune attacks. Its work covers natural killer cells for immuno-oncology, and cardiomyocytes, neurons and islet cells for regenerative medicine. Founder and CEO Luhan Yang leads the company. In September 2023, it raised more than CNY 100 million in pre-Series B funding from new investor Jinkong Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in